75 related articles for article (PubMed ID: 6285115)
1. Fluorescent antibody to membrane antigen (FAMA) procedure for determining susceptibility to varicella: an evaluation.
Ward F; Campbell-Benzie A; Heath RB
Med Lab Sci; 1982 Jan; 39(1):33-8. PubMed ID: 6285115
[No Abstract] [Full Text] [Related]
2. Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test.
Sauerbrei A; Färber I; Brandstädt A; Schacke M; Wutzler P
J Virol Methods; 2004 Jul; 119(1):25-30. PubMed ID: 15109817
[TBL] [Abstract][Full Text] [Related]
3. A simplified immunofluorescence technique for antibody to varicella-zoster membrane antigen (FAMA).
Baba K; Yoshida M; Tawa A; Yabuuchi H; Maeda K; Takahashi M
Biken J; 1984 Mar; 27(1):23-9. PubMed ID: 6091617
[TBL] [Abstract][Full Text] [Related]
4. Seroepidemiologic survey of varicella: Value of specific fluorescent antibody test.
Gershon AA; Krugman S
Pediatrics; 1975 Dec; 56(6):1005-8. PubMed ID: 172853
[TBL] [Abstract][Full Text] [Related]
5. Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays.
Asano Y; Albrecht P; Vujcic LK; Quinnan GV; Kawakami K; Takahashi M
Pediatrics; 1983 Sep; 72(3):291-4. PubMed ID: 6310478
[TBL] [Abstract][Full Text] [Related]
6. Effect of varicella-zoster virus (VZV) fluorescent-antibody-to-membrane-antigen (FAMA) testing on sensitivity of determining VZV immunity in healthcare workers and on furlough days.
Rolando L; Schneider WJ; Steinberg S; Low S; Stiles J; Gomez L; Gershon AA; Brown AE
Infect Control Hosp Epidemiol; 2010 Sep; 31(9):972-4. PubMed ID: 20666603
[No Abstract] [Full Text] [Related]
7. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella.
Breuer J; Schmid DS; Gershon AA
J Infect Dis; 2008 Mar; 197 Suppl 2():S147-51. PubMed ID: 18419389
[TBL] [Abstract][Full Text] [Related]
8. Immunity to varicella zoster virus among young adults: a decline prior to widespread uptake of varicella vaccines.
Grotto I; Balicer RD; Smetana Z; Davidovitch N; Bar-Zeev Y; Mendelson E; Zarka S; Huerta M
Infection; 2008 Mar; 36(2):130-4. PubMed ID: 18379727
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.
Lafer MM; Weckx LY; de Moraes-Pinto MI; Garretson A; Steinberg SP; Gershon AA; LaRussa PS
Clin Vaccine Immunol; 2011 Jul; 18(7):1194-7. PubMed ID: 21613463
[TBL] [Abstract][Full Text] [Related]
10. Varicella zoster in hospital personnel: skin test reactivity to monitor susceptibility.
Steele RW; Coleman MA; Fiser M; Bradsher RW
Pediatrics; 1982 Oct; 70(4):604-8. PubMed ID: 6289236
[TBL] [Abstract][Full Text] [Related]
11. Varicella zoster antibody testing in the care of pregnant women exposed to varicella.
McGregor JA; Mark S; Crawford GP; Levin MJ
Am J Obstet Gynecol; 1987 Aug; 157(2):281-4. PubMed ID: 3039845
[TBL] [Abstract][Full Text] [Related]
12. Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection.
Chris Maple PA; Gray J; Brown K; Brown D
J Virol Methods; 2009 Apr; 157(1):90-2. PubMed ID: 19135089
[TBL] [Abstract][Full Text] [Related]
13. Persistence of immunity to live attenuated varicella vaccine in healthy adults.
Ampofo K; Saiman L; LaRussa P; Steinberg S; Annunziato P; Gershon A
Clin Infect Dis; 2002 Mar; 34(6):774-9. PubMed ID: 11830801
[TBL] [Abstract][Full Text] [Related]
14. Abortive chickenpox.
Aksoy L; Ciftçi U; Ozsoylu S
Eur J Pediatr; 1997 Mar; 156(3):248. PubMed ID: 9083772
[No Abstract] [Full Text] [Related]
15. Live attenuated varicella vaccine: the KMcC strain in healthy children.
Arbeter AM; Starr SE; Weibel RE; Neff BJ; Plotkin SA
Pediatrics; 1983 Mar; 71(3):307-12. PubMed ID: 6298698
[TBL] [Abstract][Full Text] [Related]
16. Varicella-zoster virus-specific cellular immunity in subjects given acyclovir after household chickenpox exposure.
Kumagai T; Kamada M; Igarashi C; Yuri K; Furukawa H; Chiba S; Kojima H; Saito A; Okui T; Yano S
J Infect Dis; 1999 Sep; 180(3):834-7. PubMed ID: 10438374
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to varicella virus of certain adults in the southeastern United States.
Hyams PJ; Vernon S; Eckert D
Am J Infect Control; 1984 Feb; 12(1):6-9. PubMed ID: 6322621
[TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immunity to varicella-zoster virus: an overview.
Arvin AM
J Infect Dis; 2008 Mar; 197 Suppl 2():S58-60. PubMed ID: 18419410
[No Abstract] [Full Text] [Related]
19. Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus.
Vossen MT; Gent MR; Weel JF; de Jong MD; van Lier RA; Kuijpers TW
J Infect Dis; 2004 Jul; 190(1):72-82. PubMed ID: 15195245
[TBL] [Abstract][Full Text] [Related]
20. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine.
Asano Y; Suga S; Yoshikawa T; Kobayashi I; Yazaki T; Shibata M; Tsuzuki K; Ito S
Pediatrics; 1994 Oct; 94(4 Pt 1):524-6. PubMed ID: 7936864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
